Trulieve Cannabis (TRLV) Cash & Equivalents (2020 - 2026)

Trulieve Cannabis (TRLV) has reported Cash & Equivalents for 7 consecutive years, with $352.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 7.44% year-over-year to $352.9 million; the TTM figure through Mar 2026 stood at $352.9 million (up 7.44% YoY), while the FY2025 annual figure was $255.5 million, up 7.01% from the prior year.
• Cash & Equivalents came in at $352.9 million for Q1 2026 at Trulieve Cannabis, up from $255.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $449.2 million in Q3 2025, with the low at $14.9 million in Q2 2022.
• Average Cash & Equivalents over 5 years is $250.1 million, with a median of $238.8 million recorded in 2024.
• Across the five-year window, Cash & Equivalents slumped 94.86% in 2022 and soared 923.92% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $207.2 million in 2022, then fell by 2.81% to $201.4 million in 2023, then gained by 18.59% to $238.8 million in 2024, then climbed by 7.01% to $255.5 million in 2025, then surged by 38.09% to $352.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $352.9 million, $255.5 million, and $449.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.